Bringing Groundbreaking Treatments to Patients with Psychiatric and Neurodegenerative Diseases

Unleashing unique properties and biological effects of Noble gases for treatment of PTSD, Autism, Dementia

Combining revolutionary portable inhalation device with a safe therapeutic

Accelerated pathway of clinical development

Nobilis Therapeutics is developing proprietary inhalation-based therapeutics using controlled self-administration of inert gases to address unmet medical need in the treatment of psychiatric and neurodegenerative diseases.

By leveraging data on more than 500 patients successfully treated for conditions ranging from panic disorder to autoimmune diseases, Nobilis has coupled its patent pending gas mixtures with a proprietary inhalational device to offer reproducible, standardized, and controlled patient exposure. The Company is currently advancing its technologies into human clinical trials.

News Feed

Twitter Feed

Nobilis Therapeutics @NobilisTx
A Consensus Statement of the PTSD Psychopharmacology Working Group identifies NMDA antagonists as key players in PT… https://t.co/LF9ziRtaOj
h J R
Nobilis Therapeutics @NobilisTx
CBT is not the answer for PTSD. https://t.co/W0H9guL12H
h J R
Nobilis Therapeutics @NobilisTx
On February 21st Drs. Meloni and Bogin will present Nobilis’ PTSD clinical development program to the US Congress.… https://t.co/t3zbGpaXx4
h J R
Nobilis Therapeutics @NobilisTx
In early April Nobilis Therapeutics will present the results of its clinical trial of NBTX-001 in patients with Pan… https://t.co/fQoo8rsOwJ
h J R